Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 2, 2009, Pages 199-204

  Figueroa, Carlos ^a   Brecher, Martin ^b   Hamer Maansson, Jennifer E ^b   Winter, Helen ^b  

^a Research Strategy International   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Adherence; Extended release; Pharmacokinetics; Quetiapine; Schizophrenia

Indexed keywords

BENZATROPINE MESILATE; HALOPERIDOL; LITHIUM; QUETIAPINE;

ADULT; ADVERSE OUTCOME; AGED; AGITATION; AREA UNDER THE CURVE; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG RELEASE; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; STEADY STATE; TREATMENT DURATION; VITAL SIGN;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 60049085106     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.09.026     Document Type: Article

References (18)

1. Arvanitis L.A., and Miller B.G. the Seroquel Trial 13 study group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42 (1997) 233-246
2. Ascher-Svanum H., Faries D.E., Zhu B., Ernst F.R., Swartz M.S., and Swanson J.W. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 67 (2006) 453-460
3. AstraZeneca. Seroquel US prescribing information (2006). http://www.astrazeneca http://www.astrazeneca-us.com/pi/Seroquel.pdf
4. DeVane C.L., and Nemeroff C.B. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 40 (2001) 509-522
5. Diaz E., Neuse E., Sullivan M.C., Pearsall H.R., and Woods S.W. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 65 (2004) 354-360
6. Ganesan S., Agambaram V., Randeree F., Eggens I., Huizar K., and Meulien D. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin 24 (2008) 21-32
7. Grimm S.W., Richtand N.M., Winter H.R., Stams K.R., and Reele S.B. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 61 (2006) 58-69
8. Jaskiw G.E., Thyrum P.T., Fuller M.A., Arvanitis L.A., and Yeh C. Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders. Clin Pharmacokinet 43 (2004) 1025-1035
9. Kahn R.S., Schulz S.C., Palazov V.D., Reyes E.B., Brecher M., Svensson O., et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68 (2007) 832-842
10. Keith S.J., and Kane J.M. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 64 (2003) 1308-1315
11. Mamo D.C., Uchida H., Vitcu I., Barsoum P., Gendron A., Goldstein J., and Kapur S. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry 69 (2008) 81-86
12. Möller H.-J., Johnson S., Mateva T., Brecher M., Svensson O., Miller F., et al. Evaluation of the feasibility of switching from quetiapine immediate release to quetiapine extended release in stable outpatients with schizophrenia. Int Clin Psychopharmacol 23 (2008) 95-105
13. Montross L.P., Zisook S., and Kasckow J. Suicide among patients with schizophrenia: a consideration of risk and protective factors. Ann Clin Psychiatry 17 (2005) 173-182
14. Nemeroff C.B., Kinkead B., and Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 63 Suppl 13 (2002) 5-11
15. Peuskens J., Trivedi J.K., Malyarov S., Brecher M., Svensson O., Miller F., et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized placebo-controlled trial in clinically stable patients. Psychiatry (Edgemont) 4 (2007) 34-50
16. Timdahl K., Carlsson A., and Stening G. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms. Hum Psychopharmacol 22 (2007) 315-325
17. Vieta E., Mullen J., Brecher M., Paulsson B., and Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin 21 (2005) 923-934
18. Weiden P.J., Kozma C., Grogg A., and Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 55 (2004) 886-891